FiercePharmaAsia—U.S.-China trade battle, Takeda-Shire deal insight, China’s generics push

6th April 2018 Uncategorised 0

A long list of biopharma products from China are proposed targets for additional U.S. tariffs, analysts now think the Takeda-Shire deal is “more likely than not,” China puts forward a policy package that favors generics over brands and more.

More: FiercePharmaAsia—U.S.-China trade battle, Takeda-Shire deal insight, China’s generics push
Source: fierce